NOVOCURE LTD (NVCR)
Health Care · Cancer therapy devices and oncology · NASDAQ
Novocure delivers Tumor Treating Fields therapy through wearable medical devices to treat aggressive cancers including glioblastoma, lung cancer, and pancreatic cancer.
What NOVOCURE LTD does
Novocure is a global oncology company that develops and commercializes Tumor Treating Fields (TTFields) therapy delivered through medical devices to treat various cancers. The company markets three commercial devices: Optune Gio for glioblastoma, Optune Lua for metastatic non-small cell lung cancer and malignant pleural mesothelioma, and Optune Pax for locally advanced pancreatic cancer, with regulatory approvals across the US, EU, Japan, and other markets. Novocure is advancing a pipeline of new indications and product variants while pursuing regulatory approval for additional cancer types including brain metastases from NSCLC.
Themes: ["Oncology / cancer therapy","Medical devices","Tumor Treating Fields (TTFields) technology","Glioblastoma treatment","NSCLC / lung cancer treatment","Pancreatic cancer treatment","Immunotherapy combination therapy"]
Fundamentals
- Price$17.29 as of 2026-07-09 close
- Market cap$2.0B as of 2026-07-10
- 1-year return-4.9% as of 2026-07-09 close
- Net margin-25.7% as of 2026-07-10
- Gross margin+75.4% as of 2026-07-10
- ROE-39.4% as of 2026-07-10
- Debt / equity0.59 as of 2026-07-10
- Revenue growth (YoY)+8.5% as of 2026-07-10
- Revenue CAGR (3y)+6.8% SEC XBRL
- Beta1.03 as of 2026-07-10
Key risks (from latest filing)
["Company is unprofitable with net margins at -25.66%, sustained operating losses, and accumulated deficit of $1.36 billion as of Q1 2026, raising questions about path to profitability","Regulatory and reimbursement risk: TTFields devices depend on FDA and international regulatory approvals; expanding new indications like brain metastases and accessing coverage from payers are critical to growth","Market adoption risk: Commercial success of newly approved products (Optune Lua, Optune Pax) and new indications remains uncertain; reimbursement challenges limit patient access on an individual case basis in some geographies"]
Competitors & peers
- Roche (RHHBY) - oncology and glioblastoma treatments
- Merck (MRK) - immunotherapy and cancer treatments
- Bristol Myers Squibb (BMY) - oncology therapies
- AstraZeneca (AZN) - NSCLC and pancreatic cancer treatments
- Eli Lilly (LLY) - cancer therapeutics
- Accuray (ARAY) - stereotactic radiosurgery systems for cancer treatment
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.